News
Piper Sandler analyst David Westenberg maintained a Hold rating on OncoCyte (OCX – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $2.78.
Shares of biotech corporation OncoCyte (NYSEAMERICAN:OCX) are taking off on Tuesday morning after an important deal for the company’s future. OncoCyte announced that it signed an “exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback